Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.

Publikation

Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.

Wissenschaftlicher Artikel/Review - 20.11.2023

Rubbert-Roth Andrea, Kakehasi Adriana M, Takeuchi Tsutomu, Schmalzing Marc, Palac Hannah, Coombs Derek, Liu Jianzhong, Anyanwu Samuel I, Lippe Ralph, Curtis Jeffrey R

Zitation

Rubbert-Roth A, Kakehasi A, Takeuchi T, Schmalzing M, Palac H, Coombs D, Liu J, Anyanwu S, Lippe R, Curtis J. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rheumatol Ther 2023

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Rheumatol Ther 2023

Veröffentlichungsdatum

20.11.2023

ISSN (Druck)

2198-6576

Kurzbeschreibung/Zielsetzung

This article aims to describe malignancies in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), or non-radiographic axial spondyloarthritis (nr-axSpA) treated with upadacitinib (UPA) or active comparators.